Herrera-Restrepo O, Bunniran S, Mond T, Davenport E, Wang J, Sweeney C, Marshall GS. United States physicians' knowledge, attitudes, and practices regarding meningococcal vaccination for healthy adolescents and young adults. J Adolesc Health. 2024 Feb 13. doi: 10.1016/j.jadohealth.2023.11.394
La EM, Garbinsky D, Hunter S, Poston S, Novy P, Ghaswalla P. National and state-level composite completion of recommended vaccines among adolescents in the United States, 2015-2018. J Adolesc Health. 2021 Nov;69(5):762-8. doi: 10.1016/j.jadohealth.2021.07.020
Kurosky SK, Esterberg E, Irwin DE, Trantham L, Packnett E, Novy P, Whelan J, Hogea C. Meningococcal vaccination among adolescents in the United States: a tale of two age platforms. J Adolesc Health. 2019 Jul;65(1):107-15. doi: 10.1016/j.jadohealth.2019.02.014
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Davis KL, Misurski D, Miller J, Karve S. Cost impact of complications in meningococcal disease evidence from a United States managed care population. Hum Vacci. 2011 Apr 1;7(4):458-65.
Davis KL, Misurski D, Miller JM, Bell TJ, Bapat B. Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the US. Hum Vacci. 2011 Jan 1;7(1):96-101.
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.